0001179110-18-003533.txt : 20180305 0001179110-18-003533.hdr.sgml : 20180305 20180305180725 ACCESSION NUMBER: 0001179110-18-003533 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180301 FILED AS OF DATE: 20180305 DATE AS OF CHANGE: 20180305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haviland Kate CENTRAL INDEX KEY: 0001663022 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 18667887 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORPORATION STREET 2: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2018-03-01 0 0001597264 Blueprint Medicines Corp BPMC 0001663022 Haviland Kate C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Business Officer Common Stock 2018-03-01 4 M 0 2800 36.05 A 8674 D Common Stock 2018-03-01 4 S 0 2800 90.00 D 5874 D Stock Option (Right to Buy) 36.05 2018-03-01 4 M 0 2800 0 D 2027-02-16 Common Stock 2800 122210 D The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. /s/ Christopher Frankenfield, Attorney-in-Fact 2018-03-05